利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Microfabricated cross flow filter and method of manufacture
    2.
    发明申请
    Microfabricated cross flow filter and method of manufacture 审中-公开
    微型交叉流过滤器及其制造方法

    公开(公告)号：US20060266692A1

    公开(公告)日：2006-11-30

    申请号：US11136552

    申请日：2005-05-25

    申请人： John Foster ,  John Harley ,  Steven Hovey ,  Richard Martin ,  Paul Rubel ,  Hung Nguyen

    发明人： John Foster ,  John Harley ,  Steven Hovey ,  Richard Martin ,  Paul Rubel ,  Hung Nguyen

    IPC分类号： B01D63/00

    CPC分类号： B01D61/14 ,  B01D63/00 ,  B01D65/08 ,  B01D67/0062 ,  B01D69/02 ,  B01D2321/2058 ,  G01N1/4077

    摘要： A microfabricated cross flow filter may have multiple filtration stages. The filtration stages may include microfabricated filter barriers and gaps created in a substrate, thereby allowing very tight tolerances in the filter barrier and gap dimensions to be maintained. Using the microfabrication techniques, the filter barriers can be made having arbitrary shapes, and arranged at an angle or curved with respect to the flow direction, making the pressure drop across the filtration stage more uniform in the cross flow direction.

    摘要翻译： 微制造的交叉流过滤器可以具有多个过滤阶段。 过滤阶段可以包括微制造的过滤器屏障和在衬底中产生的间隙，从而允许保持过滤器屏障和间隙尺寸的非常严格的公差。 使用微细加工技术，过滤器屏障可以制成具有任意形状，并且以相对于流动方向成一定角度或弯曲的方式布置，使跨越过滤台的压降在横向方向上更均匀。

    Predicting and Diagnosing Patients With Autoimmune Disease
    5.
    发明申请
    Predicting and Diagnosing Patients With Autoimmune Disease 审中-公开
    自身免疫性疾病的预测与诊断

    公开(公告)号：US20070269827A1

    公开(公告)日：2007-11-22

    申请号：US11750729

    申请日：2007-05-18

    申请人： John Harley

    发明人： John Harley

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： The present invention provides methods for the prediction and diagnosis of autoimmune diseases including Systemic Lupus Erythematosus using a panel of single nucleotide polymorphisms (SNPs).

    摘要翻译： 本发明提供了使用单核苷酸多态性（SNP）小组预测和诊断包括系统性红斑狼疮的自身免疫性疾病的方法。

    Assays and therapies for latent viral infection
    6.
    发明申请
    Assays and therapies for latent viral infection 失效
    潜伏病毒感染的检测和疗法

    公开(公告)号：US20060257427A1

    公开(公告)日：2006-11-16

    申请号：US11405355

    申请日：2006-04-17

    申请人： John Harley ,  Judith James ,  Kenneth Kaufman

    发明人： John Harley ,  Judith James ,  Kenneth Kaufman

    IPC分类号： A61K39/25 ,  A61K39/245

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/545 ,  A61K2039/55566 ,  C07K16/085 ,  C12N2710/16222 ,  C12N2710/16234 ,  Y02A50/386 ,  Y02A50/414

    摘要： Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

    摘要翻译： 公开了结合在病毒生命周期的潜在阶段中特异性表达的病毒蛋白质的组合物。 这些组合物结合潜在的病毒蛋白质，同时病毒蛋白质在其细胞宿主中表达，并提供靶向隐藏潜伏病毒的细胞的手段。 在优选的实施方案中，组合物是结合潜伏病毒蛋白质的细胞外区域，最优选LMP-2A，EBV潜伏蛋白的抗体，其与诊断性或细胞毒性剂缀合或固定在固体支持物上以去除感染的 细胞。 这些抗体能够区分表达EBV DNA的细胞与不表达EBV DNA的细胞。 还可以公开可用于引发这些抗体或疫苗生产的组合物。 还公开了用于产生诊断或细胞毒素试剂和基于鉴定携带潜伏病毒的细胞的病毒表位的疫苗的方法。 抗体缀合物可用于诊断测定以鉴定表达潜伏性病毒蛋白的细胞和携带潜伏病毒颗粒的人。 抗体缀合物也可用于去除被感染的细胞或杀死被感染的细胞。 或者或另外，病毒蛋白质或其部分可以用作疫苗以诱导宿主杀死受感染细胞的免疫反应。 这些方法可用于检测或治疗患有EBV等潜伏病毒的患者，以及患有诸如系统性红斑狼疮（SLE）和类风湿性关节炎（RA）等自身免疫性疾病的疾病的风险。

    Assays and therapies for latent viral infection
    7.
    发明申请
    Assays and therapies for latent viral infection 审中-公开

    公开(公告)号：US20060257428A1

    公开(公告)日：2006-11-16

    申请号：US11405365

    申请日：2006-04-17

    申请人： John Harley ,  Judith James ,  Kenneth Kaufman

    发明人： John Harley ,  Judith James ,  Kenneth Kaufman

    IPC分类号： A61K39/25 ,  A61K39/245

    CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/005 ,  C07K16/085 ,  C12N2710/16222 ,  C12N2710/16234

    摘要： Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

    Assays and therapies for latent viral infection
    9.
    发明申请
    Assays and therapies for latent viral infection 失效
    潜伏病毒感染的检测和疗法

    公开(公告)号：US20050074751A1

    公开(公告)日：2005-04-07

    申请号：US10646132

    申请日：2003-08-22

    申请人： John Harley ,  Judith James ,  Kenneth Kaufman

    发明人： John Harley ,  Judith James ,  Kenneth Kaufman

    IPC分类号： C12Q1/02 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K39/395 ,  A61K45/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/18 ,  A61P3/10 ,  A61P5/14 ,  A61P7/04 ,  A61P7/06 ,  A61P9/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/14 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P29/00 ,  A61P31/22 ,  A61P35/00 ,  A61P37/08 ,  C07K14/05 ,  C07K16/08 ,  C12Q1/70 ,  A61K39/42

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/545 ,  A61K2039/55566 ,  C07K16/085 ,  C12N2710/16222 ,  C12N2710/16234 ,  Y02A50/386 ,  Y02A50/414

    摘要： Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

    摘要翻译： 公开了结合在病毒生命周期的潜在阶段中特异性表达的病毒蛋白质的组合物。 这些组合物结合潜在的病毒蛋白质，同时病毒蛋白质在其细胞宿主中表达，并提供靶向隐藏潜伏病毒的细胞的手段。 在优选的实施方案中，组合物是结合潜伏病毒蛋白质的细胞外区域，最优选LMP-2A，EBV潜伏蛋白的抗体，其与诊断性或细胞毒性剂缀合或固定在固体支持物上以去除感染的 细胞。 这些抗体能够区分表达EBV DNA的细胞与不表达EBV DNA的细胞。 还可以公开可用于引发这些抗体或疫苗生产的组合物。 还公开了用于产生诊断或细胞毒素试剂和基于鉴定携带潜伏病毒的细胞的病毒表位的疫苗的方法。 抗体缀合物可用于诊断测定以鉴定表达潜伏性病毒蛋白的细胞和携带潜伏病毒颗粒的人。 抗体缀合物也可用于去除被感染的细胞或杀死被感染的细胞。 或者或另外，病毒蛋白质或其部分可以用作疫苗以诱导宿主杀死受感染细胞的免疫反应。 这些方法可用于检测或治疗患有EBV等潜伏病毒的患者，以及患有诸如系统性红斑狼疮（SLE）和类风湿性关节炎（RA）等自身免疫性疾病的疾病的风险。